Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 5/20 | 0.40 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL197671 | 0.85 | HSD11B1 (0.56) | HSD11B1NOTUMALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL2491458 | 0.84 | PDK2 (0.41) | HSD11B1NOTUMALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL646458 | 0.84 | HSD11B1 (0.49) | HSD11B1NOTUMALDH1A1HPGDAR | |
| Hydrochloric Acid SCHEMBL29010139 | 0.83 | HSD11B1 (0.54) | HSD11B1NOTUMALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL8022901 | 0.83 | HSD11B1 (0.54) | HSD11B1NOTUMALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL2093777 | 0.83 | ALDH1A1 (0.32) | HSD11B1NOTUMALDH1A1HPGD | |
| SCHEMBL67468 | 0.80 | ALDH1A1 (0.43) | HSD11B1NOTUMALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL17503644 | 0.77 | MEN1 (0.39) | ALDH1A1CYP3A4CYP2D6ALOX15CYP2C19 | |
| SCHEMBL30977284 | 0.74 | HSD11B1 (0.47) | HSD11B1NOTUMALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL27925987 | 0.74 | KCNN4 (0.49) | HSD11B1NOTUMALDH1A1CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3009123-A1 | MELANIN PRODUCTION INHIBITOR | Pola Chemical Industries Inc. (JP) | 2016-04-20 | — | — | EP | disclosed |
| US-20150328107-A1 | MELANIN PRODUCTION INHIBITOR | POLA CHEMICAL INDUSTRIES INC. (JP) | 2015-11-19 | — | — | US | disclosed |
| EP-2845587-A2 | Melanin production inhibitor | Pola Chemical Industries Inc. (JP) | 2015-03-11 | — | — | EP | disclosed |
| US-20140363389-A1 | MELANIN PRODUCTION INHIBITOR | POLA CHEMICAL INDUSTRIES INC. (JP) | 2014-12-11 | — | — | US | disclosed |
| US-8846012-B2 | Melanin production inhibitor | POLA CHEMICAL INDUSTRIES INC. (JP) | 2014-09-30 | — | — | US | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| EP-2380567-A1 | MELANIN PRODUCTION INHIBITOR | Pola Chemical Industries Inc. (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-20110243865-A1 | MELANIN PRODUCTION INHIBITOR | POLA CHEMICAL INDUSTRIES INC. (JP) | 2011-10-06 | — | — | US | disclosed |
| EP-1167366-B1 | AMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2010-05-05 | — | — | EP | disclosed |
| EP-1919907-A2 | HETEROCYCLIC COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-05-14 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| WO-2007026959-A2 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZ0 [B] THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | WO | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-6562849-B1 | Amine compound or pharmacologically acceptable salt thereof. These compounds are useful in the treatment and/or prophylaxis of diseases such as diabetes, hyperlipemia, arteriosclerosis, cancer, etc. | SANKYO COMPANY, LIMITED (JP) | 2003-05-13 | — | — | US | disclosed |
| US-20030078426-A1 | Amine derivative compounds | SANKYO COMPANY, LIMITED (JP) | 2003-04-24 | — | — | US | disclosed |
| EP-1167366-A1 | AMINE DERIVATIVES | Sankyo Company, Limited (JP) | 2002-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | HSD11B1 256/4885NOTUM 3827/4885ALDH1A1 355/4885 |
| US-20110243865-A1 | MELANIN PRODUCTION INHIBITOR | TYR, F12, TH | HSD11B1 418/4885NOTUM 3998/4885ALDH1A1 1292/4885 |
| US-20030078426-A1 | Amine derivative compounds | H1-10, APOB, PRMT1 | HSD11B1 413/4885NOTUM 1049/4885ALDH1A1 874/4885 |
| US-20150328107-A1 | MELANIN PRODUCTION INHIBITOR | TYR, MC1R, F12 | HSD11B1 389/4885NOTUM 3535/4885ALDH1A1 1031/4885 |
| US-20140363389-A1 | MELANIN PRODUCTION INHIBITOR | TYR, F12, MC1R | HSD11B1 447/4885NOTUM 3688/4885ALDH1A1 1187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.